


15 September 2015

Markets Announcements Office
ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000



Genetic Signatures Limited: Appointment to Board of Directors

Genetic Signatures Limited (ASX: GSS) is pleased to announce the appointment of Dr Tony Radford to the Board of Directors of the Company.

Tony Radford has a PhD from La Trobe University, and was a member of the CSIRO team that invented the QuantiFERON method for Cellular Immune based diagnostics. He later joined AMRAD in pharmaceutical research and was Head of Development in 2000 when he left to co-found the diagnostic company Cellestis Limited, which listed on the ASX in 2001. Establishing offices and operations in the USA, Europe and Japan, Cellestis developed QuantiFERON –TB Gold, the worldwide benchmark for diagnosis of tuberculosis infection. Dr Radford was CEO of Cellestis from founding until its acquisition by QIAGEN NV in 2011 for approximately \$400 million.

Genetic Signatures' Chairman, Dr Nick Samaras PhD, said: "Tony is one of Australia's most distinguished senior biotech executives and his experience will add considerable value to Genetic Signatures. We welcome him to the board in this most exciting time of the company's development."

"I am pleased to be able to join Genetic Signatures at this time" said Dr Radford. "The company has a unique technology that is just entering the international diagnostic market and I hope to be able to contribute to its success in this process"

For his work on tuberculosis diagnosis, Dr Radford is a recipient of the Clunies Ross Medal for outstanding application of science, and is a Distinguished Alumni of La Trobe University.

Dr Radford's appointment is effective immediately.

An Appendix 3X is attached to this announcement.

For further details:

Company

John Melki
Chief Executive Officer
john@geneticsignatures.com
T: +61 2 9870 7580

Media and Investor Relations

Peter Taylor
Investor Relations
peter@nwrcommunications.com.au
T: +61 412 036 231

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity:	Genetic Signatures Limited
ABN:	30 095 913 205

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Tony Radford
Date of appointment	15 September 2015

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

+ See chapter 19 for defined terms.

Appendix 3X Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Note: Provide details of the circumstances giving rise to the relevant interest.	
N/A	

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

+ See chapter 19 for defined terms.